miR-150+/c-Myb-调控PRDM1/Blimp1诱导外周B淋巴瘤细胞向末端B细胞分化机制

基本信息
批准号:81272634
项目类别:面上项目
资助金额:16.00
负责人:赵彤
学科分类:
依托单位:南方医科大学
批准年份:2012
结题年份:2013
起止时间:2013-01-01 - 2013-12-31
项目状态: 已结题
项目参与者:陈少红,韩西群,吴自勍,周新华,汤红平,代新珍,钟琳,葛娟,黎相照
关键词:
诱导分化miR150cMybB细胞淋巴瘤PRDM1
结项摘要

According to the fact that lymphoma is one of the best model exploring induced differentiation, and in mice miR-150 controls transition from pro-B to pre-B in the B lymphocytes development by targeting c-Myb. we detected that the miR-150 was lowly expressed or absent in 8 human lymphomas cell lines compared with normal B lymphocytes. To explore the mechanism by which miR-150 functions in the pathogenesis of human B-cell lymphoma, we transduced lentivirus vector expressing pre-microRNA-150 into cell lines. the preliminary results showed that the expression of BCL6 was downregulated, and PRDM1 was upregulated in the levels of mRNA and protein in the cell lines of Raji and Daudi transduced with miR-150. Immunophenotypically, both cell lines lost the expression of CD10, and Daudi cells re-expressing miR-150 acquired the expression of CD138, the marker of plasma, compared with control. Concurrent, the transcription factor c-Myb, a potential target of miR150, was downregulated in the set of re-expressing miR-150. Next, we will further conduct tests in the different cell lines and in the models of animal in vivo, employ various biological techniques to elucidate underlying the role of miR150 and the associated genes, such as c-Myb and PRDM1, playing in the differentiation therapy of human B-cell lymphomas. We predict that miR-150 will be a new therapeutic target of B-cell lymphoma in the differentiation therapy.

鉴于B淋巴瘤是探究诱导分化最好模式肿瘤,鼠miR-150负性调控c-Myb表达控制B细胞早期分化。本课题组检测了人八株淋巴瘤细胞miR-150表达,证实B淋巴瘤细胞低表达,构建了pre-micRNA-150慢病毒表达载体及miR-150的Raji150+和Daudi150+细胞亚系,发现miR-150+瘤细胞c-Myb表达减弱,生发中心标记CD10、Bcl6表达降低,浆细胞分化开关基因PRDM1表达明显升高,出现浆细胞标记CD138表达。在以往基础上,本项目进行基因转染和干扰、miRNA转染和表达阻断、体内和体外等实验,调控B淋巴瘤细胞miR-150表达,观测靶基因c-Myb和末端B细胞分化密切相关基因PRDM1等变化,探究miR-150诱导B淋巴瘤细胞再分化机制,用基因表达谱和免疫沉淀及双荧光素酶分析相关信号通路。获得成功,将会为B淋巴瘤诱导分化治疗提供新的分子靶点及新型研究平台。

项目摘要

鉴于B淋巴瘤是探究诱导分化最好模式肿瘤,鼠miR-150负性调控c-Myb表达控制B细胞早期分化。本课题组检测了人八株淋巴瘤细胞miR-150表达,证实B淋巴瘤细胞低表达,构建了pre-micRNA-150慢病毒表达载体及miR-150的Raji150+、Daudi150+和OCI-Ly10150+细胞亚系,发现miR-150+瘤细胞c-Myb表达减弱,生发中心标记CD10、Bcl6表达降低,浆细胞分化开关基因PRDM1表达明显升高,出现浆细胞标记CD138表达。在以往基础上,本项目进行基因转染和干扰、miRNA转染和表达阻断等实验,调控B淋巴瘤细胞miR-150表达,观测靶基因c-Myb和末端B细胞分化密切相关基因PRDM1等变化,探究miR-150诱导B淋巴瘤细胞再分化机制,用生物信息学和免疫沉淀分析相关信号通路。获得成功,将会为B淋巴瘤诱导分化治疗提供新的分子靶点及新型研究平台。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Influencing factors of carbon emissions in transportation industry based on CD function and LMDI decomposition model: China as an example

Influencing factors of carbon emissions in transportation industry based on CD function and LMDI decomposition model: China as an example

DOI:10.1016/j.eiar.2021.106623
发表时间:2021
2

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

DOI:10.3389/fcell.2021.735374
发表时间:2021
3

MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway

MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway

DOI:10.1002/cam4.1029.
发表时间:2017
4

视网膜母细胞瘤的治疗研究进展

视网膜母细胞瘤的治疗研究进展

DOI:
发表时间:2018
5

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

DOI:10.1016/j.fitote.2020.104491
发表时间:2020

赵彤的其他基金

批准号:81071941
批准年份:2010
资助金额:30.00
项目类别:面上项目
批准号:61705160
批准年份:2017
资助金额:25.00
项目类别:青年科学基金项目
批准号:51147002
批准年份:2011
资助金额:10.00
项目类别:专项基金项目
批准号:30670812
批准年份:2006
资助金额:8.00
项目类别:面上项目
批准号:81470013
批准年份:2014
资助金额:30.00
项目类别:面上项目
批准号:51407110
批准年份:2014
资助金额:24.00
项目类别:青年科学基金项目
批准号:39970692
批准年份:1999
资助金额:10.00
项目类别:面上项目
批准号:81000856
批准年份:2010
资助金额:20.00
项目类别:青年科学基金项目
批准号:30270739
批准年份:2002
资助金额:20.00
项目类别:面上项目
批准号:50605037
批准年份:2006
资助金额:25.00
项目类别:青年科学基金项目
批准号:30770908
批准年份:2007
资助金额:30.00
项目类别:面上项目

相似国自然基金

1

弥漫大B细胞淋巴瘤中LMP1癌基因下调B细胞终末分化调控因子Blimp1基因的作用机制及预后预测研究

批准号:81360352
批准年份:2013
负责人:李新霞
学科分类:H0810
资助金额:40.00
项目类别:地区科学基金项目
2

间质干细胞通过wnt信号通路调控B细胞的外周分化治疗抗体介导排斥反应的机制研究

批准号:81670680
批准年份:2016
负责人:王长希
学科分类:H0507
资助金额:58.00
项目类别:面上项目
3

弥漫性大B细胞淋巴瘤中microRNA调控PRDM1基因甲基化表达的机制研究

批准号:81071942
批准年份:2010
负责人:张轶文
学科分类:H0810
资助金额:34.00
项目类别:面上项目
4

弥漫大B细胞淋巴瘤中PRDM1/BLIMP-1异常失活及化疗耐药机制研究

批准号:81700193
批准年份:2017
负责人:夏奕
学科分类:H0810
资助金额:20.00
项目类别:青年科学基金项目